Recent tariff measures affecting pharmaceutical products and
ingredients have introduced new compliance and cost considerations
for manufacturers, distributors, and importers operating in Canada
and abroad.
Overview of Recent Developments
At the beginning of April, the Trump administration (the
“Administration”) introduced a
two-fold tariff strategy affecting pharmaceuticals. Reciprocal
tariffs were implemented under the International Emergency
Economic Powers Act, imposing global reciprocal tariffs on
nearly all imports into the U.S. Certain classes of products are
exempt, including those covered by statutory exclusions, those
identified in Annex II of Executive Order 14257, and select goods
– such as pharmaceutical products – subject to pending
investigations under Section 232 of the Trade Expansion
Act.
